An Open-Label, Noncomparative Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis
Principal Investigator: Edythe A. Albano, MD
Source: Fujisawa Healthcare, Inc.
Amount: Per patient enrolled
Term: 1999 - present
An Open-Label, Noncomparative Study of FK463 for the Treatment of Invasive Aspergillosis
Principal Investigator: Edythe A. Albano, MD
Source: Fujisawa Healthcare, Inc.
Amount: Per patient enrolled
Term: 1999 - present
A Phase 1, Open-Label Study of the Safety and Pharmacokinetics of Repeated Dose Micafungin as Antifungal Prophylaxis in Children and Adolescents Undergoing Stem Cell Transplantation
Principal Investigator: Edythe A. Albano, MD
Source: Astellas Pharma
Amount: Per case reimbursement
Term: 2008 - 2009
A Phase II, Open-Label Study of Clofarex in Pediatric Patients with Refractory or Relapsed Acute Myelogenous Leukemia
Principal Investigator: Edythe A. Albano, MD
Source: Ilex Products
Amount: Per patient enrolled
Term: 2003 - present
Development of a Laboratory Kit for Neutrophil Priming
Principal Investigator: Daniel R. Ambruso, MD
Source: Colorado Bioscience Technology Grant, UCD
Amount: $156,000/yr
Term: 2007 - 2008
Evaluation of Effects of CP-34,131 on Neutrophil Function
Principal Investigator: Daniel R. Ambruso, MD
Source: Pfizer, Inc.
Amount: $2,000/yr
Term: 1997 - 2006
Minor Antigen-Matched Red Cell Transfusion for Sickle Cell Disease
Principal Investigator: Daniel R. Ambruso, MD
Investigator: Rachelle Nuss, MD
Source: Bonfils Blood Center
Amount: $12,000/yr
Term: 2001 - present
Neoantigen and Biological Response Modifier Formation by the Mirasol Pathogen Reduction System for Platelet Concentrates
Principal Investigator: Daniel R. Ambruso, MD
Source: Navigant
Amount: $25,000/yr
Term: 2007 - 2008
Program in Pediatric Transfusion Medicine
Principal Investigator: Daniel R. Ambruso, MD
Source: NHLBI, NIH - 1 K07 HL088968-01
Amount: $129,600
Term: 2007 - 2012
Support for Studies of Neutrophil Function and Biochemistry
Principal Investigator: Daniel R. Ambruso, MD
Source: Bonfils Blood Center
Amount: $250,000/yr
Term: 1979 - 2008
Evaluation of Interactions between Forodesine and DNA Damaging Agents Using In Vitro Models of T Cell Acute Lymphoblastic Leukemia
Principal Investigator: Deborah A. Deryckere, PhD
Source: BioCryst Pharmaceuticals - PN200701-071-AMD01
Amount: $14,374/yr
Term: 2007 - 2008
Genetic Modifiers of von Willebrand Disease
Principal Investigator: Jorge Di Paola, MD
Source: NIH - R01 HL084086-01
Amount: $1,125,000/yr
Term: 2007 - 2012
Prevention of the Complications of Hemophilia Through Hemophilia Treatment Centers
Principal Investigator: Jorge Di Paola, MD
Source: CDC
Amount: $86,369/yr
Term: 2007 - 2008
Rural Comprehensive Care Hemophilia
Principal Investigator: Jorge Di Paola, MD
Source: Department of Human and Health Services, Iowa
Amount: $217,392/yr
Term: 2007 - 2008
U.S. Inhibitor Pilot Project
Principal Investigator: Jorge Di Paola, MD
Source: CDC
Amount: $52,392/yr
Term: 2007 - 2008
Comparative Growth Inhibition by Selectively Targeting PK-C zeta in Glioblastoma and Normal Astrocytes
Principal Investigator: Nicholas K. Foreman, MB ChB
Source: American Cancer Society
Amount: $20,000/yr
Term: 2001 - present
Genomic and Proteomic Characterization of Diffuse Pontine Glioma
Principal Investigator: Nicholas K. Foreman, MB ChB
Source: National Brain Tumor Foundation
Amount: $47,000/yr
Term: 2008 - 2009
Neuro-Oncology Fellowship to Study Oncogenic Pathways in Atypical Rhabdoid/Teratoid Tumors
Mentor: Nicholas K. Foreman, MB ChB
Source: American Brain Tumor Association
Amount: $75,000/yr
Term: 2008 - 2010
Neuro-Oncology Laboratory Support
Principal Investigator: Nicholas K. Foreman, MB ChB
Source: ARTMA Foundation
Amount: $350,000,000
Term: 2000 - present
Neurotoxicity in Pediatric Cancer Survivors: Genetic Predictors, Structural Changes, and Improvements in Radiation Therapy Planning
Mentor: Nicholas K. Foreman, MB ChB
Source: Damon Runyon Cancer Research Foundation
Amount: $150,000/yr
Term: 2008 - 2011
Poetic BSG-HGA: Laboratory Correlates
Principal Investigator: Nicholas K. Foreman, MB ChB
Source: Bristol-Myers Squibb - CA 225-296
Amount: $169,941/yr
Term: 2008 - 2009
Mechanisms of Protection of Varicella-Virus Infection against Glioblastoma
Principal Investigator: Adriana Weinberg, MD
Co-Investigator: Nicholas K. Foreman, MB ChB
Source: American Cancer Society
Amount: $50,000/yr
Term: 2007 - 2008
Development of a Next Generation Human Papillomavirus Vaccine
Co-Principal Investigators: Robert L. Garcea, MD, and Richard Schlegel, MD, PhD
Source: National Cancer Institute
Amount: $600,000/yr
Term: 2001 - present
Mechanisms in Papovavirus Assembly
Principal Investigator: Robert L. Garcea, MD
Source: National Cancer Institute, NIH - 2R01 CA37667-21
Amount: $235,000/yr
Term: 2003 - 2008
Novel Therapeutic Vaccines for Acute and Persistent Papillomavirus Infections
Principal Investigator: Robert L. Garcea, MD
Source: Bill and Melinda Gates Foundation, Grand Challenges in Global Health - 37881
Amount: $3,540,000
Term: 2005 - 2010
Treatment of Children with Newly Diagnosed Low-Stage Lymphocyte Predominant Hodgkin Disease (LPHD)
Principal Investigator: Timothy P. Garrington, MD
Source: Children’s Oncology Group
Amount: Per case reimbursement
Term: 2006 - present
Bone Marrow Transplant Database Redevelopment and Expansion Project
Principal Investigator: Roger H. Giller, MD
Source: Sean's Hope Foundation
Amount: $30,000/yr
Term: 2005 - 2007
Bone Marrow Transplant Database Redevelopment and Expansion Project
Principal Investigator: Roger H. Giller, MD
Source: TCH Research Institute
Amount: $30,000/yr
Term: 2005 - 2007
Famvir Pharmacokinetics in Children
Principal Investigator: Roger H. Giller, MD
Source: Novartis AG - G06893
Amount: $9,505/yr
Term: 2005 - 2008
A Phase III, Multicenter, Placebo-Controlled, Randomized Double-Blind Study to Evaluate the Safety and Efficacy of PROCHYMAL
Principal Investigator: Roger H. Giller, MD
Source: Osiris
Amount: $29,262/yr
Term: 2007 - present
Retrospective Study of Ambisome Prophylaxis in Pediatric Hematopoietic Stem Cell Transplant
Principal Investigator: Roger H. Giller, MD
Source: Astellas Pharmaceuticals - G06959
Amount: $14,650/yr
Term: 2005 - 2007
Multicenter Investigation of Induction of Stable Mixed Chimerism After Bone Marrow Transplantation from HLA-Identical Donors for Sickle Cell Disease
Principal Investigator: Mark Walters, MD
Local Principal Investigator: Roger H. Giller, MD
Faculty: Rachelle Nuss, MD
Source: NIH - U01 - HL-068091
Amount: $44,400
Term: 2001 - 2006
Phase 2 Trial of Pentostatin for Treatment of Refractory Chronic GVH
Principal Investigator: David Jacobsen, MD
Co-Investigator: Roger H. Giller, MD
Source: Genzyme Corporation - G06962
Amount: $4,000/yr
Term: 2005 - 2007
Clinical Fellowship Award
Principal Investigator: Neil A. Goldenberg, MD, PhD
Faculty: Marilyn J. Manco-Johnson, MD
Source: National Hemophilia Foundation
Amount: $200,000
Term: 2004 - 2007
Clinical Fellowship Program
Mentor: Neil A. Goldenberg, MD, PhD
Source: National Hemophilia Foundation
Amount: $100,000/yr
Term: 2008 - 2010
Clinical Investigation in Pediatric Thrombosis
Principal Investigator: Neil A. Goldenberg, MD, PhD
Source: NHLBI, NIH - 1 K23 HL084055-01A1
Amount: $148,520/yr
Term: 2007 - 2012
Early Career Investigator Award: Use of a Global Assay and Comparative Proteomics in Hemophilia and von Willebrand Disease
Principal Investigator: Neil A. Goldenberg, MD, PhD
Source: Bayer Healthcare Pharmaceuticals Corporation - 200703-233
Amount: $100,000/yr
Term: 2007 - 2009
Multicenter Evaluation of the Duration of Therapy for Thrombosis in Children (the Kids-DOTT Trial)
Principal Investigator: Neil A. Goldenberg, MD, PhD
Source: Eisai, Inc.
Amount: $108,671/yr
Term: 2009 - 2013
Scholar Award in Clinical/Translational Research
Principal Investigator: Neil A. Goldenberg, MD, PhD
Source: ASH
Amount: $150,000
Term: 2005 - 2007
Advancing Development and Support of the Pediatric Experimental Therapeutics Program
Principal Investigator: Lia Gore, MD
Source: Alex's Lemonade Stand
Amount: $247,000/yr
Term: 2007 - 2009
Development of Noninvasive Methods for Analysis of Tumor Progression Using a Pre-Clinical Model of Pediatric Acute Leukemia
Principal Investigator: Lia Gore, MD
Co-Principal Investigator: Deborah A. DeRyckere, PhD
Source: American Cancer Society
Amount: $20,000/yr
Term: 2006 - 2008
Development of Noninvasive Methods for Analysis of Tumor Progression Using a Pre-Clinical Model of Pediatric Acute Leukemia
Principal Investigator: Lia Gore, MD
Source: American Cancer Society
Amount: $100,000/yr
Term: 2006 - 2008
Evaluation of the Anti-Tumor Activity of SAHA Administered in Combination with 5-Azacytidine Using In Vitro and In Vivo Models of Pediatric Acute Lymphocytic Leukemia with Poor Prognosis
Principal Investigator: Lia Gore, MD
Source: Merck & Co., Inc. - LKR30891
Amount: $70,064/yr
Term: 2006 - 2010
Evaluation of the Anti-Tumor Activity of Vorinostat Administered in Combination with 5-Azacytidine Using In Vitro and In Vivo Models of Pediatric Acute Lymphocytic Leukemia with Poor Prognosis
Principal Investigator: Lia Gore, MD
Co-Principal Investigator: Deborah A. DeRyckere, PhD
Source: Merck & Co., Inc. - LKR30891
Amount: $55,584/yr
Term: 2008 - 2011
Expanding Access to New Agents for Cancer Treatment in Children
Principal Investigator: Lia Gore, MD
Source: Alex's Lemonade Stand
Amount: $100,000/yr
Term: 2006 - 2008
Experimental Therapeutics Program
Principal Investigator: Lia Gore, MD
Source: TCH Research Institute
Amount: $214,000/yr
Term: 2004 - 2007
Identification of Molecular, Biochemical, and Phenotypic Differences in Cells Expressing PAX3-FKHR and PAX7-FKHR Fusion Proteins
Principal Investigator: Lia Gore, MD
Co-Principal Investigator: Deborah A. DeRyckere, PhD
Source: Bear Necessities Pediatric Cancer Foundation - PN200604-101
Amount: $40,000
Term: 2006 - 2007
Identification of Molecular, Biochemical, and Phenotypic Differences in Cells Expressing PAX3-FKHR and PAX7-FKHR Fusion Proteins
Principal Investigator: Lia Gore, MD
Co-Principal Investigator: Deborah A. DeRyckere, PhD
Source: Milheim Foundation - 2006-05
Amount: $7,672/yr
Term: 2006 - 2007
An International, Randomized Study to Evaluate the Addition of Docetaxel to the Combination of Cisplatin -5 Flurouracil (TCF) vs. Cisplatin -5 Flurouracil (CF) in the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents
Principal Investigator: Lia Gore, MD
Source: Sanofi-aventis U.S.
Amount: $16,483/yr
Term: 2007 - 2008
In Vitro and In Vivo Characterization of the Histone Deacetylase Inhibitors SAHA and MS-275 Alone and in Combination with Other Agents in Pediatric Acute Lymphoblastic Leukemia
Principal Investigator: Lia Gore, MD
Source: Cancer League of Colorado
Amount: $26,500
Term: 2005 - 2006
Molecular Differences in Rhabdomyosarcomas with Alternative Fusion Proteins
Principal Investigator: Lia Gore, MD
Source: Milheim Foundation
Amount: $9,004
Term: 2006 - 2007
A Multicenter, Open-Label, Phase I Study of Single Agent R7112 Administered Orally in Patients with Advanced Malignancies, Except All Forms of Leukemia
Principal Investigator: Lia Gore, MD
Source: Hoffman La-Roche, Inc.
Amount: $757,666/yr
Term: 2008 - 2011
A Multicenter, Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDx5 Every Other Week in Pediatric Patients with Advanced Solid Tumors
Principal Investigator: Lia Gore, MD
Source: The Sunshine Project
Amount: $44,419/yr
Term: 2008 - present
Multiple Ascending Dose (MAD), Phase I Study of the IGF-1R Antagonist R1507 Administered as an Intravenous Infusion in Pediatric Patients with Advanced Solid Tumors
Principal Investigator: Lia Gore, MD
Source: Hoffman La-Roche, Inc.
Amount: $130,038/yr
Term: 2007 - present
Novel Agents in the Therapy of Refractory Pediatric Brain Tumors
Principal Investigator: Lia Gore, MD
Source: Morgan Adams Foundation
Amount: $50,000/yr
Term: 2008 - present
An Open-Label, Phase I Study of RHUMAB IGRF in Patients with Advanced Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
Principal Investigator: Lia Gore, MD
Source: Genentech BioOncology
Amount: $876,895/yr
Term: 2007 - present
An Open-Label Study to Assess the Pharmacokinetics of Leukovorin in Patients Receiving High-Dose Methotrexate, With or Without Voraxaze Treatment
Principal Investigator: Lia Gore, MD
Source: Protherics, Inc.
Amount: $8,100/yr
Term: 2008 - present
A Phase I, Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children with Relapsed or Refractory Acute Leukemias
Principal Investigator: Lia Gore, MD
Source: Genzyme Corporation
Amount: $14,342/yr
Term: 2007 - present
A Phase I, First-In-Human, Open-Label, Sequential Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharamcodynamics of AMG 102 in Patients with Advanced Solid Tumors
Principal Investigator: Lia Gore, MD
Source: Amgen Research
Amount: $656,190/yr
Term: 2007 - present
A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD6918 Administered Daily as a Single Agent and in Combination Treatment in Adult Patients with Refractory Solid Malignancies
Principal Investigator: Lia Gore, MD
Source: AstraZeneca
Amount: $700,960/yr
Term: 2008 - present
A Phase I, Open-Label, Multicenter Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Azacitidine and Valproic Acid in Combination in Pediatric Patients with Advanced Malignancies
Principal Investigator: Lia Gore, MD
Source: Celgene Corporation
Amount: $32,071/yr
Term: 2008 - present
A Phase I Study of ErbituxTM(Cetuximab) in Pediatric Subjects with Refractory Solid Tumors: Characterization of Serum Pharmacokinetics, Safety, and Efficacy Following Single Doses and Repeated Weekly Administration when Combined with Irinotecan
Co-Principal Investigator: Lia Gore, MD
Source: Bristol-Myers Squibb Company
Amount: $259,626/yr
Term: 2005 - 2008
A Phase I Study of Liposomal Annamycin in Children and Young Adults with Refractory or Relapsed Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Principal Investigator: Lia Gore, MD
Source: Callisto Pharmaceuticals, Inc.
Amount: $77,969/yr
Term: 2006 - present
A Phase I Study of TST10088 in Patients with Advanced Incurable Solid Tumors
Co-Principal Investigator: Lia Gore, MD
Source: Twinstrand Therapeutics
Amount: $351,875/yr
Term: 2005 - present
A Phase I Trial of Arsenic Trioxide in the Treatment of Infiltrating Gliomas of Childhood
Principal Investigator: Lia Gore, MD
Source: Cephalon, Inc.
Amount: $10,777/yr
Term: 2008 - present
A Phase II, Open-Label Study of IMC-A12 Administered as a Single Agent Every 2 Weeks in Patients with Previously-Treated Advanced or Metastatic Soft Tissue and Ewing’s Sarcoma/PNET
Principal Investigator: Lia Gore, MD
Source: ImClone Systems, Inc.
Amount: $18,492/yr
Term: 2008 - present
A Phase II Study of the Safety and Efficacy of Nimotuzumab in Pediatric Patients with Recurring Diffuse Brain Stem Glioma
Principal Investigator: Lia Gore, MD
Source: YM BioSciences, Inc.
Amount: $44,937/yr
Term: 2007 - present
Pre-Clinical Characterization of Histone Deacetylase Inhibitor Anti-Tumor Activity Using In Vitro and In Vivo Models of Pediatric Acute Lymphoblastic Leukemia
Principal Investigator: Lia Gore, MD
Co-Principal Investigator: Deborah A. DeRyckere, PhD
Source: Cancer League of Colorado - 0503-087
Amount: $4,497/yr
Term: 2005 - 2007
Pre-Clinical Evaluation of Vandetanib in Pediatric Leukemia
Principal Investigator: Lia Gore, MD
Co-Principal Investigator: Margaret Macy, MD
Source: For Julie Foundation Grant
Amount: $25,000/yr
Term: 2008 - 2010
Translational Research Project: Metabolic Markers of HDACI-Mediated Therapeutic Efficacy in Acute Leukemia
Principal Investigator: Lia Gore, MD
Co-Principal Investigator: Deborah A. DeRyckere, PhD
Source: Leukemia and Lymphoma Society
Amount: $180,018/yr
Term: 2008 - 2011
K12 Clinical Oncology Scholars Award
Principal Investigator: Madeleine Kane, MD, PhD
Co-Investigator: Lia Gore, MD
Source: NIH - CA86913
Amount: $871,500
Term: 2001 - 2008
Phase I Drug Development Program
Co-Principal Investigator: Gail S. Eckhardt, MD
Co-Investigator: Lia Gore, MD
Source: National Cancer Institute, NIH - 5U01 CA099176-03
Amount: $1,622,852
Term: 2003 - 2008
Development of a Diagnostic FISH Assay for Mer Cytogenetic Abnormalities in Lymphoblastic Leukemia and Lymphoma
Principal Investigator: Douglas K. Graham, MD, PhD
Source: UCD Technology Transfer Proof of Concept Award
Amount: $17,391
Term: 2006
Inhibition of Mer Tyrosine Kinase as a Novel Treatment for ALL
Principal Investigator: Douglas K. Graham, MD, PhD
Source: Milheim Foundation for Cancer Research
Amount: $13,636/yr
Term: 2006 - 2007
The Mer Oncogene and Merstatin: A Novel High-Impact Therapeutic Target
Principal Investigator: Douglas K. Graham, MD, PhD
Source: UCD Technology Transfer Proof of Concept Award
Amount: $100,000
Term: 2005 - 2006
Mer Receptor Tyrosine Kinase Mutational Analysis in Pediatric ALL
Principal Investigator: Douglas K. Graham, MD, PhD
Source: St. Baldrick’s Foundation
Amount: $18,600/yr
Term: 2006 - 2007
Mer Tyrosine Kinase as a Cooperative Oncogene in Leukemogenesis
Principal Investigator: Douglas K. Graham, MD, PhD
Source: G&P Foundation for Cancer Research - 30
Amount: $68,182/yr
Term: 2007 - 2010
The Mer Tyrosine Kinase as a Potential Therapeutic Target in Lymphoblastic Leukemias
Principal Investigator: Douglas K. Graham MD, PhD
Source: Cancer League of Colorado - 63066647
Amount: $30,000
Term: 2005 - 2006
A Novel Biologically Targeted Agent for the Treatment of Non-Small Cell Lung Cancer
Principal Investigator: Douglas K. Graham, MD, PhD
Source: Colorado Bioscience Discovery Grant
Amount: $174,800/yr
Term: 2007 - 2008
Novel Biologically Targeted Therapy Against the Mer Receptor Tyrosine Kinase in the Treatment of Pediatric ALL
Principal Investigator: Douglas K. Graham, MD, PhD
Source: Damon Runyon Cancer Research Foundation - CI-39-07
Amount: $150,000/yr
Term: 2007 - 2010
Oncogenic Potential of Mer in Pediatric Acute Lymphoblastic Leukemia
Principal Investigator: Douglas K. Graham, MD, PhD
Source: National Childhood Cancer Foundation
Amount: $100,000
Term: 2005 - 2006
Soluble Mer Receptor Tyrosine Kinase as a Novel Therapeutic Agent for Pediatric T Cell Acute Lymphoblastic Leukemia
Principal Investigator: Douglas K. Graham, MD, PhD
Source: American Cancer Society Institutional Research Grant
Amount: $20,000/yr
Term: 2006 - 2007
Target Validation of the Mer Receptor Tyrosine Kinase in the Treatment of Pediatric Astrocytomas
Principal Investigator: Douglas K. Graham, MD, PhD
Source: TCH Research Institute
Amount: $30,000/yr
Term: 2007 - 2008
Transforming Potential of the Mer Receptor Tyrosine Kinase in E2A-PBX1 Leukemia
Principal Investigator: Douglas K. Graham, MD, PhD
Source: Cure Search - 200709-061
Amount: $30,000/yr
Term: 2006 - 2008
The Use of Merstatin in the Treatment of Thrombosis
Principal Investigator: Douglas K. Graham, MD, PhD
Source: UCD Technology Transfer Proof of Concept Award
Amount: $62,000
Term: 2006
Analysis of MerTK Contribution to Initiation of Leukemogenesis
Principal Investigator: Luis Brandao, MD
Mentor: Douglas K. Graham, MD, PhD
Source: Cancer League of Colorado
Amount: $30,000/yr
Term: 2008 - 2009
Effect of Overexpression of the Receptor Tyrosine Kinase Mer in a Transgenic Mouse Model
Principal Investigator: Dana Salzberg, MD
Mentor: Douglas K. Graham, MD, PhD
Source: Research Scholar Award, TCH Research Institute
Amount: $55,000
Term: 2004 - 2006
J. Patrick Barnes Grants for Nursing Research and Evidence-Based Practice Projects
Principal Investigator: Molly Hemenway, ND, RN, AC/CPNP
Source: The DAISY Foundation
Amount: $2,500/yr
Term: 2007 - 2009
Best Pharmaceuticals for Children Award
Principal Investigator: Stephen P. Hunger, MD
Source: Children’s Oncology Group - 2 U10 CA98543-Reaman
Amount: $11,662/yr
Term: 2008 - 2009
Clinical Trials Core
Principal Investigator and Co-Chair: Stephen P. Hunger, MD
Source: Pediatric Cancer Foundation Sunshine Project and H. Lee Moffitt Cancer Center and Research Institute
Amount: $12,780/yr
Term: 2006 - 2009
COG ALL Committee
Principal Investigator and Chair: Stephen P. Hunger, MD
Source: Children’s Oncology Group - 2 U10 CA98543-Reaman
Amount: $46,650
Term: 2008 - 2009
COG ALL Committee
Principal Investigator and Vice Chair (Biology): Stephen P. Hunger, MD
Source: Children’s Oncology Group - U10 CA 98543-Reaman
Amount: $41,996/yr
Term: 2007 - 2008
Oncology Fellow Training Grant
Principal Investigators: Stephen P. Hunger, MD, and Douglas K. Graham, MD, PhD
Co-Investigator: Ralph R. Quinones, MD
Source: National Cancer Institute, NIH - CA 082086-05
Amount: $1,356,550
Term: 2005 - 2010
Specialized Center of Research in Targeted Therapies for Infant Leukemia
Principal Investigator: Stephen P. Hunger, MD
Source: Leukemia and Lymphoma Society
Amount: $5,000/yr
Term: 2007 - 2008
COG Specimen Banks Advance Pediatric Cancer
Principal Investigator: Greg Reaman, MD
Investigator: Stephen P. Hunger, MD
Source: National Cancer Institute, NIH - U24 CA 114766
Amount: $11,256/yr
Term: 2005 - 2010
Axl Receptor Tyrosine Kinase as a Therapeutic Target for Pediatric Myeloid Leukemia
Principal Investigator: Amy K. Keating, MD
Mentor: Douglas K. Graham, MD, PhD
Source: Brent Ely Foundation - 2580861
Amount: $50,000/yr
Term: 2007 - 2009
Educational Support for Amy Keating
Principal Investigator: Amy K. Keating, MD
Source: Loan Repayment, NIH
Amount: $37,800/yr
Term: 2006 - present
Mer Receptor Tyrosine Kinase as a Biologic Marker and Therapeutic Target for Pediatric Leukemia
Principal Investigator: Amy K. Keating, MD
Source: Children’s Cancer Research Fund
Amount: $40,000/yr
Term: 2006 - 2007
Mer-Targeted Therapy for Human Acute Lymphoblastic Leukemia
Principal Investigator: Amy K. Keating, MD
Source: Amgen Oncology Institute Fellow
Amount: $40,000/yr
Term: 2006 - 2007
The Role of Mer and Axl Receptor Tyrosine Kinases in Pediatric Astrocytoma
Principal Investigator: Amy K. Keating, MD
Source: Loan Repayment Program, NIH
Amount: $34,000/yr
Term: 2008 - 2009
The Role of Mer and Axl Tyrosine Kinases in Pediatric Astrocytoma
Principal Investigator: Amy K. Keating, MD
Source: St. Baldrick’s Foundation
Amount: $110,000/yr
Term: 2008 - 2011
The Role of Mer and Axl Tyrosine Kinases in Non-Small Cell Lung Cancer
Principal Investigator: Rachel Linger, MD
Mentor: Douglas K. Graham, MD, PhD
Source: Lung Cancer Research Foundation
Amount: $50,000/yr
Term: 2008 - 2009
The Role of Mer and Axl Tyrosine Kinases in Non-Small Cell Lung Cancer
Principal Investigator: Rachel Linger, MD
Mentor: Douglas K. Graham, MD, PhD
Source: NCI SPORE in Lung Cancer, UCD Cancer Center
Amount: $45,866/yr
Term: 2008 - 2009
The Preclinical Development of Vandetanib for Treatment of Pediatric Leukemia
Principal Investigator: Margaret E. Macy, MD
Source: Thorkildsen Research Fellowship
Amount: $35,000/yr
Term: 2008 - 2009
Creative Arts Therapist
Principal Investigator: Jennifer R. Madden, RN, MSN, CPNP
Source: Gabby Krause Foundation
Amount: $12,500/yr
Term: 2006 - 2009
COG Principal Investigator Salaries
Principal Investigator: Kelly W. Maloney, MD
Source: Children’s Oncology Group
Amount: $41,986/yr
Term: 2008 - 2009
COG Study Chair
Principal Investigator: Kelly W. Maloney, MD
Source: CureSearch
Amount: $27,990/yr
Term: 2008 - 2009
Psychosocial Outcomes of Pediatric Brain Tumors
Principal Investigator: Kelly W. Maloney, MD
Source: American Cancer Society
Amount: $72,000/yr
Term: 2003 - 2008
Clinical Fellowship Training Grant
Principal Investigator: Marilyn J. Manco-Johnson, MD
Source: National Hemophilia Foundation
Amount: $100,000/yr
Term: 2006 - 2008
Develop, Implement, and Ensure Comprehensive Hemophilia Evaluation and Management of Clinics for Federal Region VIII
Principal Investigator: Marilyn J. Manco-Johnson, MD
Source: Maternal and Child Health Bureau, HRSA, HHS - 5 H30 MC00008-18-00
Amount: $344,000/yr
Term: 2007 - 2010
FDA Prelicensure Study of Haemocomplettan-P: Human Plasma-Derived Viral Inactivated Fibrinogen Concentrate
Principal Investigator: Marilyn J. Manco-Johnson, MD
Source: CSL Behring
Amount: $35,000/yr
Term: 2007 - 2010
Pharmaceutical Clinical Trials
Principal Investigator: Marilyn J. Manco-Johnson, MD
Source: Bayer Pharmaceuticals
Amount: $389,576/yr
Term: 2007 - 2010
Pilot Project in Thrombophilia/Thrombosis Centers: Integrating Prevention Services for Persons with Bleeding and Clotting Disorders
Principal Investigator: Marilyn J. Manco-Johnson, MD
Consultant: Elizabeth Pounder, PA-C
Source: National Center on Birth Defects and Developmental Disabilities, CDC
Amount: $145,000/yr
Term: 2007 - 2012
Preventing Complications in Persons with Hemophilia
Principal Investigator: Marilyn J. Manco-Johnson, MD
Source: CDC
Amount: $87,000/yr
Term: 2006 - 2009
Prevention of the Complications of Hemophilia through Hemophilia Treatment Centers
Principal Investigator: Marilyn J. Manco-Johnson, MD
Source: Boehringer Ingelheim
Amount: $300,000/yr
Term: 2006 - 2011
Provide Education, Community Outreach, and Direct Patient Care for Hemophilia and Related Bleeding Disorders
Principal Investigator: Marilyn J. Manco-Johnson, MD
Source: State of Colorado
Amount: $212,000/yr
Term: 2007 - 2010
SPINART: Adult Prophylaxis Study
Principal Investigator: Marilyn J. Manco-Johnson, MD
Source: Bayer Healthcare Pharmaceuticals
Amount: $137,267
Term: 2008 - 2011
Program Project Grant for the Molecular and Clinical Biology of von Willebrand Disease
Principal Investigator: Robert Montgomery, MD
Co-Investigator: Marilyn J. Manco-Johnson, MD
Source: NHLBI, NIH - PO 1 HL 081588-01
Amount: $10,000/yr
Term: 2007 - 2010
Effect of Nitric Oxide for Restoring Hemostatic and Inflammatory Balance in Sickle Cell Disease
Principal Investigator: Rachelle Nuss, MD
Source: INO Therapeutics
Amount: $54,350
Term: 2005 - 2007
A Prospective, Multicenter, Double-Blind, Randomized Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis
Principal Investigator: Rachelle Nuss, MD
Source: INO Therapeutics
Amount: $96,736
Term: 2005 - 2009
Comprehensive Sickle Cell Centers Priapism
Principal Investigator: Kathryn Hassell, MD
Co-Investigator: Rachelle Nuss, MD
Source: NHLBI, NIH - PN 200701-190
Amount: $38,962/yr
Term: 2007 - 2008
Extension Trial of an Oral Chelator ICL-670
Principal Investigator: Kathryn Hassell, MD
Investigator: Rachelle Nuss, MD
Source: Novartis AG
Amount: $119,690/yr
Term: 2005 - 2009
A Phase I/II Trial of Sildenafil for Sickle Cell-Associated Pulmonary Hypertension Clinical Trial
Principal Investigator: David Badesch, MD
Sub-Investigators: Kathryn Hassell, MD, and Rachelle Nuss, MD
Source: NHLBI, NIH - HB06-06
Amount: $217,917/yr
Term: 2006 - 2010
Identification of Drug Targets in AML Using a shRNA Library and Microarray Technology
Principal Investigator: Christopher Porter, MD
Source: St. Baldrick's Foundation
Amount: $7,500/yr
Term: 2007 - 2008
Impairing HPRT Function Improves the Efficacy of Treatment of Leukemia with 6-Thioguanine
Principal Investigator: Christopher Porter, MD
Source: UCD Cancer Center - CA103680-04
Amount: $20,000/yr
Term: 2007 - 2008
Impairment of Checkpoint Activation by the Oncogene E2a-Hlf Contributes to Leukemogenesis
Principal Investigator: Christopher Porter, MD
Source: W. M. Thorkildsen Research Fellowship
Amount: $25,000/yr
Term: 2005 - 2006
Modeling Treatment-Related Acute Myelogenous Leukemia
Principal Investigator: Christopher Porter, MD
Source: Brent Eley/Brian Hicks Research Award
Amount: $100,000/yr
Term: 2005 - 2007
Modeling Treatment-Related Acute Myelogenous Leukemia
Principal Investigator: Christopher Porter, MD
Source: Cancer League of Colorado
Amount: $30,000/yr
Term: 2005 - 2006
Paul Calabresi Clinical Oncology Scholars Award
Principal Investigator: Christopher Porter, MD
Source: UCD Cancer Center
Amount: $150,000/yr
Term: 2008 - 2013
A Pilot Study to Determine the Frequency and Significance of BCL-6 Expression and Mutation in Post-Transplantation Lymphoproliferative Disorder in Children
Principal Investigator: Richard D. Krugman, MD
Program Director: Ronald J. Sokol, MD
Investigator: Christopher Porter, MD
Co-Investigator: Edythe A. Albano, MD
Source: Pediatric General Clinical Research Center, NCRR, NIH - M01 RR00069
Amount: $10,000/yr
Term: 2003 - 2006
National Cord Blood Bank Inventory Effort
Principal Investigator: Brian Freed, PhD
Co-Investigator: Ralph R. Quinones, MD
Source: HRSA, HHS
s Amount: $1,000,000/yr
Term: 2006 - 2016
An Animal Model of TRALI
Principal Investigator: Christopher C. Silliman, MD, PhD
Source: NHLBI, NIH - R0-1 HL-59355-05
Amount: $200,000/yr
Term: 2003 - 2008
The Role of Human Antibodies in TRALI
Principal Investigator: Christopher C. Silliman, MD, PhD
Source: Pall Corporation
Amount $2,100
Term: 2007
The Role of Mirasol in Inhibiting the Accumulation of Pro-Inflammatory Lipids in Stored Blood and Platelets Concentrates
Principal Investigator: Christopher C. Silliman, MD, PhD
Source: Navigant
Amount: $81,671
Term: 2008
Role of the White Cell in Sickle Cell Disease
Principal Investigator: Christopher C. Silliman, MD, PhD
Investigator: Rachelle Nuss, MD
Source: Clinical Translational Research Center
Term: 2004 - 2008
Trauma Primes Cells
Principal Investigator: Christopher C. Silliman, MD, PhD
Source: NIGMS, NIH - 2 P50 GM-49222
Amount $182,570/yr
Term: 2005 - 2010
Trauma Primes Cells (Project II): The Role of Neutral Lipophilic Compounds from Stored Blood in Pulmonary Endothelial Activation
Principal Investigator: Anirban Banejee, PhD
Co-Principal Investigator: Christopher C. Silliman, MD, PhD
Source: National Institute of General Medical Sciences, NIH - 2 P50 GM-4922
Amount: $239,000/yr
Term: 2005 - 2010
DNA Methylation in Medulloblastoma
Principal Investigator: Rajeev Vibhakar, MD
Source: Alex’s Lemonade Stand
Amount: $30,000/yr
Term: 2007 - 2008
Microrna Function in Medulloblastoma
Principal Investigator: Rajeev Vibhakar, MD
Source: NINDS, NIH - KO8
Amount: $772,912/yr
Term: 2008 - 2013
Microrna Function in Medulloblastoma
Principal Investigator: Rajeev Vibhakar, MD
Source: Bear Necessities Children’s Cancer Fund
Amount: $40,000/yr
Term: 2007 - 2008
Lymphotropic Polyomavirus Infection and Its Potential Role in Lymphoid Cancer in Humans
Principal Investigator: Richard D. Krugman, MD
Program Director: Ronald J. Sokol, MD
Investigator: Michael Wang, MD
Source: Pediatric General Clinical Research Center, NCRR, NIH - M01 RR00069
Amount: $22,896/yr
Term: 2005 - 2006
Lymphotropic Polyomavirus: Natural History and Potential Role in Lymphoid Cancer in Humans
Principal Investigator: Michael Wang, MD
Source: American Cancer Society, UCD Cancer Center Seed Grant
Amount: $20,000/yr
Term: 2005 - 2006
Lymphotropic Polyomavirus: Natural History and Potential Role in Lymphoid Cancer in Humans
Principal Investigator: Michael Wang, MD
Source: St. Baldrick's Foundation
Amount: $5,000/yr
Term: 2006 - 2007
Mechanisms in Polyoma and Papillomavirus Assembly
Principal Investigator: Michael Wang, MD
Source: National Cancer Institute - 5 R01 CA 037667-23
Amount: $112,125/yr
Term: 2008 - 2009
Polyomavirus Infection and Human Malignancy
Principal Investigator: Michael Wang, MD
Source: Cancer League of Colorado
Amount: $30,000/yr
Term: 2008 - 2009
Polyomavirus Infection: Potential Role in Childhood Cancer
Principal Investigator: Michael Wang, MD
Source: St. Baldrick's Foundation
Amount: $49,320/yr
Term: 2008 - 2009